Michael Klichinsky
CSO, Nava Therapeutics
Michael Klichinsky is listed as CSO, Nava Therapeutics. Michael is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Michael. Is this you? Claim this profile.
About
Michael Klichinsky, PharmD, PhD, is an experienced biotechnology CSO and founder with expertise in ex vivo and in vivo cell therapies for oncology, autoimmunity, and fibrosis. He is Chief Scientific Officer of Nava Therapeutics, where he leads the development of in vivo CAR-T and targeted LNP therapeutics. Previously, Mike served as co-founder and CSO of Carisma Therapeutics and co-founder of Chymal Therapeutics. Mike holds a PhD from the University of Pennsylvania, where he developed CAR-M therapy, and a PharmD from the Philadelphia College of Pharmacy.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- The Big Debate: In vivo CAR-T - is it the future or just more hype? Speaker · 19 January 2027
- Session 8: How and where is innovation in both systemic and local delivery enabling the migration of advanced therapies into emerging indications and therapeutic areas? Speaker · 21 January 2027
- Spotlight Speaker · 21 January 2027
Spoke alongside
People who have shared a session with Michael at events on B2DB.
- Sheena Smith Assistant Professor of Biotechnology, School of Chemistry, Chemical Engineering and Biotechnology (CCEB) · Nanyang Technological University, Singapore 1 shared session